慢性阻塞性肺疾病患者血浆D-二聚体、纤维蛋白原及纤维蛋白（原）降解产物检测的临床意义

目的探讨血浆D-二聚体（D-D）、纤维蛋白原（FIB）及纤维蛋白（原）降解产物（FDP）在慢眭阻塞性肺疾病（C0PD）检测中的临床意义。方法检测150例COPD患者及80例健康体检者的血浆D．D、FIB及FDP水平并进行比较。结果COPD患者血浆D-D、FIB及FDP水平明显高于健康体检者[（2．16±0．61）mg／LLL（0．55±0．04）mg／L、（5．88±1．52）g／L比（3．12±0．35）g／L、（7．18±1．63）mg／L比（3．62±1．55）mg／L]，差异有统计学意义（P〈0．01）。结论监测血浆D-D、FIB及FDP水平对COPD患者体内存在的高凝状态和原发性与继发性纤溶亢进提供了可靠的依据。

Clinical signifcance of plasma D-dimer,fibrinogen and fbrin/fibrinogen degradation product detection in patients with chronic obstructive pulmonary disease

Objective To investigate clinical significance of plasma D-dimer （D-D）, fibrinogen （FIB） and fibrin/fibrinogen degradation product （FDP） in patients with chronic obstructive pulmonary disease （COPD）. Methods The level of plasma D-D, FIB and FDP in 150 patients with COPD and 80 healthy persons were detected, and compared. Results The level of plasma D-D, FIB and FDP in COPD patients were significantly higher than those in healthy persons[ （2.16 ± 0.61 ） mg/L vs.（0.55 ± 0.04） mg/L, （5.88 ± 1.52） g/L vs.（3.12± 0.35） g/L, （7.18 ±1.63） mg/L vs. （3.62 ±1.55） mg/L] ,there were significant differences （P 〈 0.01 ）. Conclusion Monitoring the level of plasma D-D, FIB and FDP in COPD patients can provide reliable basis in hypercoagulable state and primary and secondary hyperfibrinolysis.